Effectiveness and safety of influenza vaccination in children: European perspective

Vaccine

Volumn 29, Issue 43, 2011, Pages 7529-7534

  Heikkinen, Terho ^a,b   Heinonen, Santtu ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Children; Effectiveness; Inactivated; Influenza vaccine; Live attenuated; Safety; Trivalent

Indexed keywords

AS 03; INFLUENZA VACCINE; LIVE ATTENUATED INFLUENZA VACCINE; LIVE VACCINE; MIFAMURTIDE; PLACEBO; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ACUTE OTITIS MEDIA; ADJUVANT THERAPY; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DUODENITIS; EPIDEMIC; EUROPE; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; NARCOLEPSY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVACCINATION; RHINORRHEA; SEASONAL INFLUENZA; SIDE EFFECT; SKIN REDNESS; TREATMENT RESPONSE; VIRUS STRAIN; WHEEZING; WINTER;

CHILD; CHILD, PRESCHOOL; EUROPE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; PUBLIC POLICY; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 80053459613     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.011     Document Type: Article

References (57)

1. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225-231.
2. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342:232-239.
3. Neuzil K.M., Zhu Y., Griffin M.R., Edwards K.M., Thompson J.M., Tollefson S.J., et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002, 185:147-152.
4. Heikkinen T., Silvennoinen H., Peltola V., Ziegler T., Vainionpää R., Vuorinen T., et al. Burden of influenza in children in the community. J Infect Dis 2004, 190:1369-1373.
5. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355:31-40.
6. McIntosh K., Lieu T. Is it time to give influenza vaccine to healthy infants?. N Engl J Med 2000, 342:275-276.
7. Heikkinen T., Booy R., Campins M., Finn A., Olcén P., Peltola H., et al. Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts. Eur J Pediatr 2006, 165:223-228.
8. Monto A.S. Seasonal influenza and vaccination coverage. Vaccine 2010, 28:D33-D44.
9. Usonis V., Anca I., André F., Chlibek R., Ivaskeviciene I., Mangarov A., et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children. BMC Infect Dis 2010, 10:168.
10. Blank P.R., Schwenkglenks M., Szucs T.D. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009, 58:446-458.
11. VENICE. Final Report National Seasonal Influenza Vaccination Survey in Europe. Collaboration between VENICE project and ECDC, 2007 [accessed 18.07.2011]. http://venice.cineca.org/Influenza_Study_Report_v1.0.pdf.
12. Salo H., Kilpi T., Sintonen H., Linna M., Peltola V., Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006, 24:4934-4941.
13. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, 2:CD004879.
14. Zambon M.C., Stockton J.D., Clewley J.P., Fleming D.M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001, 358:1410-1416.
15. Heikkinen T., Ziegler T., Peltola V., Lehtinen P., Toikka P., Lintu M., et al. Incidence of influenza in Finnish children. Pediatr Infect Dis J 2003, 22:S204-S206.
16. Peltola V., Reunanen T., Ziegler T., Silvennoinen H., Heikkinen T. Accuracy of clinical diagnosis of influenza in outpatient children. Clin Infect Dis 2005, 41:1198-1200.
17. Weinberg G.A., Szilagyi P.G. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 2010, 201:1607-1610.
18. Zangwill K.M., Belshe R.B. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 2004, 23:189-200.
19. Negri E., Colombo C., Giordano L., Groth N., Apolone G., La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 2005, 23:2851-2861.
20. Manzoli L., Schioppa F., Boccia A., Villari P. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J 2007, 26:97-106.
21. Heikkinen T., Ruuskanen O., Waris M., Ziegler T., Arola M., Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991, 145:445-448.
22. Hoberman A., Greenberg D.P., Paradise J.L., Rockette H.E., Lave J.R., Kearney D.H., et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003, 290:1608-1616.
23. Shuler C.M., Iwamoto M., Buxton Bridges C., Marin M., Neeman R., Gargiullo P., et al. Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004. Pediatrics 2007, 119:e587.
24. Szilagyi P.G., Fairbrother G., Griffin M.R., Hornung R.W., Donauer S., Morrow A., et al. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons. Arch Pediatr Adolesc Med 2008, 162:943-951.
25. Eisenberg K.W., Szilagyi P.G., Fairbrother G., Griffin M.R., Staat M., Shone L.P., et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics 2008, 122:911-919.
26. Joshi A.Y., Iyer V.N., St Sauver J.L., Jacobson R.M., Boyce T.G. Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case-control study. Vaccine 2009, 27:4457-4461.
27. Cochran L.W., Black S., Klein N.P., Dekker C.L., Lewis E., Reingold A.L. Vaccine effectiveness against laboratory-confirmed influenza in infants: a matched case control study. Hum Vaccin 2010, 6:729-735.
28. Heinonen S., Silvennoinen H., Lehtinen P., Vainionpää R., Ziegler T., Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011, 11:23-29.
29. Katayose M., Hosoya M., Haneda T., Yamaguchi H., Kawasaki Y., Sato M., et al. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine 2011, 29:1844-1849.
30. Kelly H., Jacoby P., Dixon G.A., Carcione D., Williams S., Moore H.C., et al. Vaccine effectiveness against laboratory-confirmed influenza in healthy young children: a case-control study. Pediatr Infect Dis J 2011, 30:107-111.
31. Heikkinen T., Ruuskanen O. Effectiveness of influenza vaccine to prevent acute otitis media. JAMA 2004, 291:692-693. [author response 693-4].
32. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199:159-167.
33. Skowronski D.M., De Serres G., Dickinson J., Petric M., Mak A., Fonseca K., et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009, 199:168-179.
34. Beran J., Wertzova V., Honegr K., Kaliskova E., Havlickova M., Havlik J., et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009, 9:2.
35. Skowronski D.M., Hottes T.S., Chong M., De Serres G., Scheifele D.W., Ward B.J., et al. Randomized controlled trial of dose-response to influenza vaccine in children 6-23 months of age. Pediatrics 2011, 128:e276-e289.
36. Calcagnile S., Zuccotti G.V. The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 2010, 10:191-200.
37. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23:300-306.
38. Salleras L., Dominguez A., Pumarola T., Prat A., Marcos M.A., Garrido P., et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 2006, 24:6638-6642.
39. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
40. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27:6291-6295.
41. Carmona A., Omenaca F., Tejedor J.C., Merino J.M., Vaman T., Dieussaert I., et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010, 28:5837-5844.
42. Andrews N., Waight P., Yung C.F., Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011, 203:32-39.
43. European Medicines Agency. Assessment Report, EMA/789489/2010, 2010 [accessed 18.7.2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001101/WC500103711.pdf.
44. Rhorer J., Ambrose C.S., Dickinson S., Hamilton H., Oleka N.A., Malinoski F.J., et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009, 27:1101-1110.
45. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
46. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
47. Block S.L., Heikkinen T., Toback S.L., Zheng W., Ambrose C.S. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011, 30:203-207.
48. France E.K., Glanz J.M., Xu S., Davis R.L., Black S.B., Shinefield H.R., et al. Safety of the trivalent inactivated influenza vaccine among children. Arch Pediatr Adolesc Med 2004, 158:1031-1036.
49. Hambidge S.J., Glanz J.M., France E.K., McClure D., Xu S., Yamasaki K., et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 2006, 296:1990-1997.
50. Englund J.A., Walter E., Black S., Blatter M., Nyberg J., Ruben F.L., et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J 2010, 29:105-110.
51. Künzi V., Dornseiff M., Horwath J., Hartmann K. Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27:1261-1265.
52. Black S., Della Cioppa G., Malfroot A., Nacci P., Nicolay U., Pellegrini M., et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010, 28:7331-7336.
53. National Institute for Health and Welfare, Finland. Increased risk of narcolepsy observed among children and adolescents vaccinated with Pandemrix, 2011 [accessed 18.07.2011]. http://www.thl.fi/en_US/web/en/pressrelease%3Fid=24103.
54. Medical Products Agency, Sweden. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations: results of a case inventory study by the MPA in Sweden during 2009-2010, 2011 [accessed 18.07.2011]. http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf.
55. WHO Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination, 2011 [accessed 18.07.2011]. http://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/index.html.
56. Ambrose C.S., Yi T., Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain of live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses 2011, 10.1111/j. 1750-2659.2011.00243.x.
57. Halasa N., Englund J.A., Nachman S., Weinberg G.A., Huber V.C., Allison K., et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 2011, 29:4110-4115.